Kawasaki Disease with Encephalitis

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis that predominantly affects medium‑size arteries, especially the coronary arteries. When the inflammation spreads to the central nervous system (CNS), patients may develop encephalitis—a rare but serious complication characterized by brain inflammation.

KD is the leading cause of acquired heart disease in children in developed countries, whereas KD‑associated encephalitis is much less common, reported in roughly 0.1–0.3% of KD cases. The condition most often occurs in children under 5 years, with a male‑to‑female ratio of approximately 1.5–1.8:1.

Symptoms

Symptoms of Kawasaki disease with encephalitis can be divided into two groups: classic KD features and CNS manifestations.

Classic Kawasaki Disease Features

• Fever lasting ≥5 days – often >39 °C (102.2 °F) and unresponsive to antipyretics.
• Conjunctival injection – bilateral, non‑purulent redness of the eyes.
• Oral mucosal changes – cracked lips, “strawberry” tongue, erythema of the oropharynx.
• Peripheral extremity changes – erythema of hands/feet, edema, later desquamation (peeling).
• Polymorphous rash – can be maculopapular, erythema multiforme‑like, or urticarial.
• Cervical lymphadenopathy – usually unilateral, >1.5 cm in diameter.

Encephalitis‑Specific Symptoms

• Altered mental status – irritability, lethargy, difficulty waking, or confusion.
• Seizures – generalized or focal, may be the first sign of CNS involvement.
• Headache – often severe, resistant to routine analgesics.
• Vomiting – may be non‑bilious and not related to gastrointestinal KD symptoms.
• Focal neurological deficits – weakness, facial droop, speech disturbances.
• Photophobia and neck stiffness – signs that can mimic meningitis.
• Behavioral changes – agitation or inconsolable crying in younger children.

Causes and Risk Factors

The exact trigger for KD remains unknown, but current research suggests a multifactorial model:

• Infectious agents – viral (e.g., adenovirus, coronavirus) or bacterial superantigens may initiate an abnormal immune response.
• Genetic predisposition – polymorphisms in ITPKC, CASP3, and HLA‑related genes increase susceptibility. Siblings of affected children have a 10‑fold higher risk.
• Immune dysregulation – over‑activation of cytokines (TNF‑α, IL‑6, IL‑1β) leads to widespread vascular inflammation.
• Age – children 6 months to 5 years are most affected; infants <6 months have higher risk of atypical KD and CNS complications.
• Sex – males are ~1.5‑times more likely to develop KD and its neurologic complications.
• Seasonality – peaks in winter‑spring in the Northern Hemisphere suggest an environmental trigger.

Diagnosis

KD is a clinical diagnosis; encephalitis is identified when neurological symptoms accompany KD and other causes have been excluded.

Clinical Criteria

• Fever ≥5 days plus ≥4 of the 5 classic KD signs (conjunctivitis, oral changes, extremity changes, rash, lymphadenopathy).
• If incomplete KD is suspected (fewer than 4 signs), laboratory and echocardiographic findings assist in diagnosis.

Laboratory Tests

• Elevated inflammatory markers: CRP >3 mg/dL, ESR >40 mm/hr.
• White blood cell count ↑ (often >15 × 10⁹/L) with neutrophilia.
• Thrombocytosis (platelets >450 × 10⁹/L) after the first week.
• Normocytic anemia, hypoalbuminemia, and elevated liver enzymes may be present.
• CSF analysis (lumbar puncture) in encephalitis: typically mild pleocytosis, normal glucose, and protein elevation.

Imaging and Other Studies

• Echocardiography – baseline and serial exams to detect coronary artery aneurysms (CAA). Approximately 20–25% of untreated KD develop CAA; early IVIG reduces this to <5%.
• Brain MRI – may show T2/FLAIR hyperintensities, especially in the basal ganglia, thalami, or cerebral cortex.
• EEG – helpful when seizures occur; may reveal diffuse slowing.
• Serology/PCR for infectious agents – performed to rule out viral encephalitis (e.g., HSV, enterovirus).

Treatment Options

Management must address both the systemic vasculitis and the CNS inflammation.

First‑Line Therapy for Kawasaki Disease

• Intravenous immunoglobulin (IVIG) – 2 g/kg single infusion within 10 days of fever onset. Reduces CAA risk by ~80%.¹
• Aspirin – high‑dose (80–100 mg/kg/day) until afebrile for 48 h, then low‑dose antiplatelet (3–5 mg/kg/day) for ≈6–8 weeks or longer if coronary abnormalities persist.

Therapy Specific to Encephalitis

• Corticosteroids – methylprednisolone 30 mg/kg/day (max 1 g) for 3 days followed by a taper, used when neurological signs are prominent or IVIG response is inadequate.²
• Second‑line agents (for IVIG‑resistant KD): infliximab (5 mg/kg), cyclosporine, or anakinra (IL‑1 receptor antagonist). These have shown benefit in controlling both vasculitis and CNS inflammation.
• Anticonvulsants – levetiracetam or phenobarbital for seizure control, titrated to the child’s weight and renal function.
• Supportive care – maintain hydration, monitor electrolytes, and treat fever aggressively.

Long‑Term Management

• Monthly echocardiograms for the first year, then every 6–12 months based on coronary status.
• Low‑dose aspirin continued indefinitely if coronary aneurysms persist.
• Consultation with pediatric neurology for ongoing neurocognitive assessments.

Living with Kawasaki Disease with Encephalitis

Families face both acute recovery and long‑term monitoring. Practical tips include:

• Medication adherence – set alarms, use pill organizers, and keep a treatment log.
• Temperature monitoring – record fevers twice daily; break the fever‑threshold (>38.5 °C) may signal relapse.
• Cardiac follow‑up – attend every scheduled echocardiogram; learn to recognize chest pain, shortness of breath, or palpitations.
• Neurodevelopmental surveillance – watch for learning difficulties, attention problems, or motor delays; early intervention services improve outcomes.
• School communication – provide a health summary to teachers; arrange for accommodations if fatigue or cognitive issues arise.
• Vaccinations – most are safe after IVIG; live vaccines (e.g., MMR, varicella) should be delayed 11 months after IVIG infusion per CDC guidance.
• Family support – join KD support groups (e.g., The Kawasaki Disease Foundation) for shared experiences and resources.

Prevention

Because the trigger is unknown, primary prevention is limited. However, steps can reduce the severity and recurrence:

• Early recognition – educate caregivers on the fever + rash + eye redness triad.
• Prompt treatment – IVIG within 10 days markedly lowers coronary and CNS complications.
• Infection control – maintain hand hygiene and avoid exposure to sick individuals, especially during KD peaks.
• Genetic counseling – families with multiple KD cases may benefit from counseling about recurrence risk.

Complications

If untreated or inadequately treated, KD with encephalitis can lead to:

• Coronary artery aneurysms – may cause myocardial infarction, sudden cardiac death, or need for coronary bypass.
• Persistent neurologic deficits – cognitive impairment, seizures, or motor weakness lasting months to years.
• Myocarditis or heart failure – secondary to widespread vasculitis.
• Thrombosis – aneurysmal coronary segments can clot, leading to ischemia.
• Systemic organ involvement – hepatitis, renal dysfunction, or respiratory distress.
• Recurrent KD – occurs in 2–4% of patients, often with a more severe course.

When to Seek Emergency Care

References

• 1. Newburger JW, et al. "Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease." Circulation. 2020;141:e377‑e400. PMID: 32609733.
• 2. Burns JC, Glodé MP. "Kawasaki disease." Lancet. 2022;399:353‑364. PMID: 34926254.
• 3. McCrindle BW, et al. "Kawasaki Disease: Clinical Presentation and Management." JAMA. 2021;326(7):648‑658.
• 4. Centers for Disease Control and Prevention. "Kawasaki Disease (Mucocutaneous Lymph Node Syndrome)." Updated 2023. https://www.cdc.gov/kawasaki/
• 5. Mayo Clinic. "Kawasaki disease." 2024. https://www.mayoclinic.org
• 6. World Health Organization. "Neurological complications of systemic vasculitis." WHO Guideline 2022.